TY - JOUR
T1 - Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma
AU - Alinari, Lapo
AU - Musuraca, Gerardo
AU - Tani, Monica
AU - Stefoni, Vittorio
AU - Gabriele, Annalisa
AU - Marchi, Enrica
AU - Fina, Mariapaola
AU - de Vivo, Antonio
AU - Pileri, Stefano
AU - Baccarani, Michele
AU - Zinzani, Peter Luigi
PY - 2005/10
Y1 - 2005/10
N2 - In order to assess the efficacy and toxicity profile of oxaliplatin, a third generation platinum derivate active against several solid tumors, we carried out a study in a group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL). Between August 2003 and May 2004, 19 pretreated patients were enrolled in a phase II trial and were treated with oxaliplatin. The drug was administered intravenously on day 1 of a 21-day schedule, at a dose of 130 mg/m2 for a total of 6 cycles. One (5%) patient achieved complete remission (CR) and 5 patients (27%) had partial response (PR), thus giving an overall response rate of 32%. The patient in CR suffered from an aggressive B NHL. One of the 5 patients in PR had an aggressive B NHL, whereas the remaining 4 had an indolent B NHL. The treatment was well tolerated with minimal hematologic and extrahematologic toxicity. These data suggest and confirm the efficacy and low toxicity of oxaliplatin in the treatment of patients with heavily pretreated NHL. Further trials using oxaliplatin alone or in combination with other conventional drugs are needed.
AB - In order to assess the efficacy and toxicity profile of oxaliplatin, a third generation platinum derivate active against several solid tumors, we carried out a study in a group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL). Between August 2003 and May 2004, 19 pretreated patients were enrolled in a phase II trial and were treated with oxaliplatin. The drug was administered intravenously on day 1 of a 21-day schedule, at a dose of 130 mg/m2 for a total of 6 cycles. One (5%) patient achieved complete remission (CR) and 5 patients (27%) had partial response (PR), thus giving an overall response rate of 32%. The patient in CR suffered from an aggressive B NHL. One of the 5 patients in PR had an aggressive B NHL, whereas the remaining 4 had an indolent B NHL. The treatment was well tolerated with minimal hematologic and extrahematologic toxicity. These data suggest and confirm the efficacy and low toxicity of oxaliplatin in the treatment of patients with heavily pretreated NHL. Further trials using oxaliplatin alone or in combination with other conventional drugs are needed.
KW - Chemotherapy
KW - Non-Hodgkin's lymphoma
KW - Oxaliplatin
KW - Pretreated
UR - http://www.scopus.com/inward/record.url?scp=26944499050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26944499050&partnerID=8YFLogxK
U2 - 10.1080/10428190500178779
DO - 10.1080/10428190500178779
M3 - Article
C2 - 16252433
AN - SCOPUS:26944499050
SN - 1042-8194
VL - 46
SP - 1437
EP - 1440
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 10
ER -